Partners: Sintef Energi As, THE CARBON CAPTURE AND STORAGE ASSOCIATION ASBL
Support Stakeholders on Carbon Capture Utilisation and Storage of ETIP ZEP and IWG9 The overarching goal of this proposal is to bring together and further develop a strong inclusive network of CCUS stakeholders – effectively interconnecting and coordinating the activities of CCUS European Technology Innovation Platforms (ETIP ZEP) and the CCUS SET Plan Implementation Plan Working Group (IWG9) – to support the development and implementation of the SET Plan. Supporting the alignment and efficient coordination of stakeholders – including industry, researchers, public authorities, civil society – in order to accelerate the delivery of the CCUS research and innovation (R&I) activities and to progress the emerging policy priorities at EU and national level for the implementation of CCUS, will be crucial over the coming years for Europe to reach the ambitious climate targets for 2030 and 2050. This will be achieved by efficiently aligning and coordinating the activities of ETIP ZEP and the IWG9 in a joint work programme; establishing networks and other fora to enable the stakeholders to collaborate and coordinate effectively, pooling expertise, experience and resources to address common challenges; engaging also with other programmes and external stakeholders; facilitating engagement and creating greater interaction and cohesion between the different CCUS activities; supporting the CCUS community to develop clear strategies and recommendations; accompanied by a strong continuous programme for outreach, dissemination and communication.
Partners: Sintef Energi As, NANOTAG BIOTECHNOLOGIES GMBH, NIL
Many bacteria that cause infectious diseases develop resistance to not only the primary antibiotic treatments available in the clinic but also to drugs of last resort which often require long treatment periods and come with significant side effects. At the same time many promising lead compounds with high activity and wide therapeutic windows have failed to progress to clinical trials due to poor solubility, protein absorption or other difficulties in formulation (e.g. low drugability). LeadtoTreat proposes a new solution to these challenges by introduction of a platform for future infection treatment enabling targeted delivery of novel lead compounds with low drugability as well as synergistic combinations of antibiotics and potentiators in a nano-formulation. A novel dual targeting approach, with both direct targeting toward the pathogenic bacteria as well as to areas of inflammation will be employed. This platform technology will be demonstrated by converting a highly active, but insoluble and protein binding, novel compound into targeted nano-formulations for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections with proven in vivo and in vitro safety. Furthermore, LeadtoTreat aims to identify novel synergistic combinations of antibiotics and potentiators and convert these into highly active targeted nano-formulations for treatment of MRSA infections. LeadToTreat will have significant impact on the future treatment of microbial infections, by demonstrating a pathway to co-delivery of synergistic combination of existing antibiotics as well a path way to revitalize the huge library of abandoned low-drugability lead compounds. From an innovation perspective, it is expected to also develop broadly applicable targeting tools (for MRSA, and roadmap for other indications). The project will be managed by SINTEF (Norway) involving Narodowy Instytut Lekow (National Medicine Institute, NMI, Poland) and NanoTag Biotechnologies GmbH (NTB, Germany).
Partners: Sintef Energi As, INSERM, FUNDACIO CENTRE DE REGULACIO GENOMICA, INVENIAM
Lung cancer is the leading cause of cancer-related deaths, with 1.8 million deaths expected globally in 2021. Lung adenocarcinomas (LUAD) represent 1/3 of all lung cancer cases. Despite notable advances, current treatments remain ineffective, resulting in <25% survival beyond 5 years. Due to the high heterogeneity of molecular abnormalities driving lung cancers, targeted therapies are applicable to only a small subset of patients. There is therefore an urgent unmet need for developing novel therapeutic approaches generally applicable to LUAD patients. Alternative pre-mRNA splicing (AS) allows the synthesis of different protein variants from a single gene by differential selection of exonic sequences. Increased inclusion of exon 9 of the gene NUMB encodes a protein isoform that promotes cancer cell proliferation. This occurs in the vast majority of LUAD tumours, correlating with worse disease prognosis. Supported by the ERC PoC VALSL, we developed an innovative therapeutic approach based on the use of Antisense Oligonucleotides (AONs) that regulate NUMB AS. Our proprietary AONs correct NUMB pathological splicing, inhibit cancer cell proliferation and reduce tumour growth in four different mouse models of LUAD, including 2 Patient-Derived Xenograft models. With support from the EIC Transition, we will bring this technology to a stage where it is ready to be validated in clinical trials. We will optimise our lead AONs by improving their chemistry, formulation and administration and will carry out regulatory pre-clinical studies. These will pave the way to the first application of AON-based splicing modulation in clinical oncology. To commercialise this technology, we also aim to develop the business plan for a spin-off company, AON Therapeutics. In the long term, our project has the potential to generate compounds, presentations and delivery methods that can be applicable to other target AS events and/or cancer types, as well as to other AS-related diseases.
Partners: CCSA, UKRI, Sintef Energi As, CO2 VALUE EUROPE AISBL
The overarching objective of Project IMplementation Plan for Actions on CCUS Technologies in the SET Plan - IMPACTS9 - is to support the realisation of the SET Plan Implementation Plan on CCS and CCU (hereafter referred to as CCUS). Multiple studies have highlighted that CCUS technologies are expected to play a critical role in the decarbonisation of the European energy and industrial sectors. However, to date CCUS has not been developed in Europe to the extent needed if the EU is to deliver on its climate goals and support the transition to a low carbon economy. It is important that there is a renewed focus on the development of CCUS projects in Europe. In 2016 the European Commission, SET-Plan countries, and industry, outlined a Declaration of Intent for CCUS containing 10 targets for 2020, the combination of which will, if delivered, represent a material step towards commercialisation of CCUS technologies in Europe. A SET-Plan Temporary Working Group 9 was established to develop an Implementation Plan which set out eight Research & Innovation (R&I) Activities which can help to realise the 2020 CCUS targets. The Implementation Plan was approved by the European Commission in September 2017. IMPACTS9 will support delivery of the R&I activities outlined in the Implementation Plan for CCUS through the provision of coordination and support to the key public and private stakeholders that are well placed to progress the SET-Plan Implementation Plan actions in the near term. IMPACTS9 will establish sub-groups to support delivery of the R&I activities and progress CCUS. Each work package is designed to support the work of these sub-groups in delivering the R&I activities. The consortium is composed of organisations highly representative of these stakeholders and will engage with them for their active contribution in the implementation of the SET Plan.
Partners: UCC, Sintef Energi As, VGA, YAVIN FOUR CONSULTANTS,UNIPESSOAL LDA
IMPACT is a collaborative research and innovation project which aims to develop and demonstrate a next-generation testing approach for Wave Energy Converters (WECs). The proposed 250kW Dual Hardware-In-the-Loop (DHIL) testing platform is based on a technology which expands the capabilities of the already established Hardware-In-the-Loop technique. The DHIL platform combines together: • one rig for testing the entire drivetrain either linear or rotary, from input mechanical to grid compliant power; • one rig for testing structural components and mooring lines, either in dry or wet environment. The DHIL platform is therefore expected to test subsystems impacting on the 75% of the Levelized Cost Of Electricity (LCOE) of a wave energy converter. The novel methodologies proposed by the IMPACT project reduce the test duration by 50% with respect to a typical endurance test and focus on key aspects such as reliability, performance and survivability. Clear quantitative, test-derived metrics will be produced to characterize these aspects, including also techno-economic and environmental impact assessment of WECs. A test campaign involving subsystems of different device types will be undertaken during the IMPACT project to demonstrate the DHIL testing platform capabilities. A Technical Advisory Board made up of WEC developers will directly benefit of the campaign results and will provide external guidance for making the DHIL testing platform a suitable product for the international market. At the end of the project a novel platform for all the wave energy converter types will be delivered, contributing to a drastic acceleration in their progress through laboratory tests and leading to a rapid advancement from TRL 3 to TRL 5. A publicly released deliverable will describe the project results regarding the novel DHIL testing approach, methodologies and metrics to facilitate their implementation in future testing practices for the development of wave energy technologies.